Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Travera Inc
Endeavor Biomedicines, Inc.
Incyte Corporation
Incyte Corporation
Taproot Health
University of Florida
Xencor, Inc.
Incyte Corporation
AbbVie
AbbVie
Novartis
Incyte Corporation
Incyte Corporation
Novartis
Stanford University
University of Chicago
Mannkind Corporation